Another nested case–control study based on the French national health care insurance system (SNDS) database also demonstrated a substantially increased incidence risk of overall thyroid cancer (HR: 1.58, 95% CI: 1.27–1.95),43 compared with T2D patients without GLP‐1 RAs users. The gene discussed is GLP1R; the disease is thyroid cancer.